AbbVie (NYSE:ABBV) Shares Down 1.5% – What’s Next?

AbbVie Inc. (NYSE:ABBV) shares fell 1.5% during trading on Friday . The stock traded as low as $255.58 and last traded at $256.27. 4,679,176 shares changed hands during trading, a decline of 30% from the average session volume of 6,685,035 shares. The stock had previously closed at $260.21.

Trending Headlines about AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Etentamig delivers a major pipeline win: AbbVie’s investigational BCMA×CD3 bispecific T-cell engager met both primary endpoints in the Phase 3 CERVINO trial for relapsed or refractory multiple myeloma. The drug produced a 74% objective response rate versus 45.7% for standard therapies and reduced the risk of disease progression or death by 60% (hazard ratio 0.40). The results could support regulatory filing and position etentamig to compete in the growing multiple-myeloma market. AbbVie Announces Positive Topline Results from the Phase 3 CERVINO Trial
• Positive Sentiment: Apogee acquisition expands immunology exposure: AbbVie completed its approximately $10.9 billion purchase of Apogee Therapeutics, adding late-stage IL-13 antibody zumilokibart for atopic dermatitis and additional asthma programs. The deal strengthens AbbVie’s post-Humira growth pipeline, although management expects near-term earnings dilution before the transaction becomes accretive, reportedly in 2032. AbbVie Completes Acquisition of Apogee Therapeutics
• Neutral Sentiment: Guidance was reaffirmed: AbbVie maintained its 2026 adjusted EPS outlook of $13.87 to $14.07 and third-quarter guidance of $3.84 to $3.88. The full-year range is broadly in line with the approximately $14.02 analyst consensus, offering little new upside or downside surprise.
• Negative Sentiment: Humira erosion remains a key overhang: Humira revenue continues to fall as biosimilar competition intensifies, raising questions about how long AbbVie can sustain dividend growth and replace the former blockbuster’s cash flow. Growth from Skyrizi and Rinvoq helps offset the decline, but investors remain focused on execution and the company’s elevated valuation. AbbVie’s Humira Cash Cow Is Shrinking

Analysts Set New Price Targets

Several research analysts recently issued reports on the company. Wolfe Research raised AbbVie from a “peer perform” rating to an “outperform” rating and set a $300.00 target price on the stock in a research report on Thursday, August 13th. Canaccord Genuity Group raised their price target on AbbVie from $282.00 to $290.00 and gave the stock a “buy” rating in a report on Monday, August 3rd. Morgan Stanley restated an “overweight” rating and set a $296.00 price objective on shares of AbbVie in a report on Monday, August 3rd. Cantor Fitzgerald increased their price objective on shares of AbbVie from $265.00 to $285.00 and gave the company an “overweight” rating in a research report on Monday, August 3rd. Finally, Sanford C. Bernstein reiterated a “market perform” rating on shares of AbbVie in a research note on Tuesday, June 23rd. Two analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and five have given a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $275.95.

AbbVie Stock Performance

The firm’s 50 day simple moving average is $254.57 and its 200 day simple moving average is $229.87. The firm has a market capitalization of $452.78 billion, a price-to-earnings ratio of 72.39, a PEG ratio of 1.18 and a beta of 0.29.

AbbVie (NYSE:ABBV) last issued its earnings results on Friday, July 31st. The company reported $3.65 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.61 by $0.04. The firm had revenue of $16.99 billion during the quarter, compared to analysts’ expectations of $16.80 billion. AbbVie had a net margin of 9.80% and a negative return on equity of 422.07%. The firm’s revenue was up 10.2% compared to the same quarter last year. During the same quarter last year, the company posted $2.97 earnings per share. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. As a group, sell-side analysts forecast that AbbVie Inc. will post 14.05 earnings per share for the current year.

AbbVie Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Friday, August 14th. Shareholders of record on Wednesday, July 15th were paid a dividend of $1.73 per share. The ex-dividend date was Wednesday, July 15th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 2.7%. AbbVie’s dividend payout ratio (DPR) is presently 195.48%.

Insider Activity at AbbVie

In other news, EVP Nicholas Donoghoe sold 32,710 shares of the company’s stock in a transaction dated Friday, August 14th. The stock was sold at an average price of $250.00, for a total value of $8,177,500.00. Following the sale, the executive vice president owned 74,430 shares in the company, valued at $18,607,500. This represents a 30.53% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 0.06% of the stock is owned by insiders.

Institutional Investors Weigh In On AbbVie

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. ACT Advisors LLC. grew its position in AbbVie by 2.5% during the second quarter. ACT Advisors LLC. now owns 1,688 shares of the company’s stock valued at $425,000 after buying an additional 41 shares during the period. Willner & Heller LLC raised its position in shares of AbbVie by 0.7% in the second quarter. Willner & Heller LLC now owns 5,852 shares of the company’s stock worth $1,472,000 after acquiring an additional 43 shares during the period. B.O.S.S. Retirement Advisors LLC boosted its stake in shares of AbbVie by 3.1% during the 2nd quarter. B.O.S.S. Retirement Advisors LLC now owns 1,427 shares of the company’s stock worth $359,000 after acquiring an additional 43 shares in the last quarter. Fielder Capital Group LLC boosted its stake in shares of AbbVie by 1.7% during the 2nd quarter. Fielder Capital Group LLC now owns 2,532 shares of the company’s stock worth $637,000 after acquiring an additional 43 shares in the last quarter. Finally, Guardian Wealth Advisors LLC NC grew its position in shares of AbbVie by 0.4% during the 2nd quarter. Guardian Wealth Advisors LLC NC now owns 11,906 shares of the company’s stock valued at $2,996,000 after acquiring an additional 43 shares during the period. Institutional investors and hedge funds own 70.23% of the company’s stock.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.